Dividend compounder review

SMMT

Summit Therapeutics PLC · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score25.00/100
Confidence72.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 7.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 8.0 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 3.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 7.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-1.1B
Free Cash Flow$-323.6M
FCF Covers DividendUnknown
Debt / Equity3.67
P/E-
Revenue Growth 5Y-
Net Margin0.0%
ROE-2.7%
Price vs Trend-18.7%
3Y Return428.7%
5Y Return109.7%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Debt to equity is elevated at 3.67.
Dividend diary

Activity record

SMMT dividend review warning Warning · Warning

Debt to equity is elevated at 3.67.